Medicare Coverage for Leukemia and Lymphoma: Drugs, CAR-T, and Costs

Two patients with the same blood cancer can owe wildly different amounts under Medicare. The one taking an oral targeted pill at home pays at most $2,100 a year, because Part D has an annual cap. The one receiving infusion therapy pays 20 percent coinsurance under Part B—which has no cap at all. And a patient headed for CAR-T cell therapy faces a third structure entirely, where the setting of the infusion decides whether the exposure is bounded or ruinous. Which lane your treatment falls into is the single biggest cost variable in Medicare coverage for leukemia and lymphoma.

The lane assignment is mostly an accident of pharmacology—whether the best drug for your CLL, lymphoma, or leukemia happens to be a pill or an IV bag. This article lays out where each major treatment falls, what it costs in each setting, and which supplemental coverage closes the dangerous gaps.

Does Medicare Cover Leukemia and Lymphoma Treatment?

Yes — Medicare covers the full spectrum of blood cancer care, from initial diagnosis through treatment and long-term survivorship. Coverage spans Parts A, B, and D, with which part applies depending on how and where each service is delivered.

What Medicare covers:

• Diagnostic workup: complete blood counts, bone marrow biopsy, PET-CT staging, flow cytometry, and molecular testing (BCR-ABL, IGHV, TP53, FLT3) — under Part B
• Oral targeted pills (BTK inhibitors, BCL-2 inhibitors, TKIs for CML) — under Part D, capped at $2,100 per year
• Infused chemotherapy and monoclonal antibodies (rituximab, bendamustine, R-CHOP) — under Part B at 20% coinsurance
• CAR-T cell therapy — under Part A (inpatient) or Part B (outpatient) depending on the care setting
• Hospitalization, stem cell transplant, and bone marrow transplant — under Part A
• Supportive drugs (anti-nausea, G-CSF/filgrastim) — under Part B (infused) or Part D (oral)
• Hospice care — under Part A for end-stage disease

What Medicare does NOT cover:

• Dental care required before transplant (pre-transplant dental clearance is not a covered Medicare benefit)
• Personal care and custodial home care unrelated to a skilled nursing need
• Experimental treatments outside a qualifying clinical trial

2026 Cost Snapshot — Key Blood Cancer Services:

The single most important cost fact in blood cancer: oral targeted pills under Part D are capped at $2,100 per year — a profound protection for patients on expensive drugs like ibrutinib ($14,000+/month list price). Infused drugs under Part B have no annual cap, which is why supplemental coverage (Medigap Plan G) is the most consequential financial decision for anyone expecting IV therapy or CAR-T.

Diagnosis and Monitoring Under Part B

Getting to a precise blood-cancer diagnosis—and monitoring it over time—runs through Part B at 80 percent after the $283 deductible (2026), leaving you 20 percent coinsurance:

• Blood counts (CBC), peripheral smear, and chemistry panels — billed as clinical laboratory tests, generally at no coinsurance
• Bone marrow biopsy and aspiration — 20 percent coinsurance
• Flow cytometry, cytogenetics (FISH), and molecular testing for markers such as BCR-ABL, IGHV mutation status, TP53/del(17p), and FLT3 — these guide drug choice and are covered as diagnostic lab work
• CT, PET-CT, and MRI for staging lymphoma — 20 percent coinsurance
• Lymph node biopsy — 20 percent coinsurance

Because many blood cancers are monitored for years (CLL in particular is often “watched and waited” before any treatment begins), these recurring Part B charges add up even before drug therapy starts.

The Core Cost Split: Oral Pills (Part D) vs. Infused Drugs (Part B)

The single most important financial fact in blood-cancer treatment is where your drug is administered, because that determines which part of Medicare pays and how much protection you have. This is the same Part B vs. Part D drug split that drives cost across nearly every serious diagnosis—but blood cancers show the divide at its most extreme.

Oral targeted therapy — Part D, capped at $2,100

A wave of oral targeted agents has transformed treatment of CLL, lymphoma, and some leukemias. Because you swallow them at home, they fall under Part D:

• BTK inhibitors — ibrutinib (Imbruvica), acalabrutinib (Calquence), zanubrutinib (Brukinsa) for CLL and certain lymphomas
• BCL-2 inhibitor — venetoclax (Venclexta)
• FLT3 and IDH inhibitors — midostaurin (Rydapt), gilteritinib (Xospata), ivosidenib (Tibsovo) for acute myeloid leukemia
• Tyrosine kinase inhibitors for CML — imatinib (now generic), dasatinib, nilotinib, bosutinib
• PI3K and other oral agents for relapsed lymphoma

These drugs carry list prices of $10,000–$18,000 per month, but thanks to the 2025 Part D redesign, your total out-of-pocket for all covered Part D drugs is now capped at $2,100 per year. That cap is the difference between a manageable cost and financial catastrophe. You can also spread the $2,100 over the year using Medicare Prescription Payment Plan monthly installments. For a fuller walkthrough of tiers, the cap, and the payment plan, see our guide to Medicare Part D.

Infused chemotherapy and antibodies — Part B, no annual cap

Drugs given by IV or injection in a clinic or hospital outpatient department fall under Part B, where you owe 20 percent coinsurance with no annual limit:

• Monoclonal antibodies — rituximab (Rituxan and biosimilars), obinutuzumab (Gazyva), and others, central to most lymphoma and CLL regimens
• Infusion chemotherapy — bendamustine, cytarabine, anthracyclines, and combination regimens such as R-CHOP
• Azacitidine/decitabine for myelodysplastic syndrome and AML (oral versions exist and shift to Part D)

A single rituximab infusion can run several thousand dollars, and a full lymphoma regimen of six or more cycles means 20 percent of a very large number, repeatedly, with no cap. This is where beneficiaries without supplemental coverage face the most danger.

The counterintuitive result

A patient on an expensive oral BTK inhibitor under Part D pays no more than $2,100 a year, while a patient on infused rituximab-based chemo under Part B can owe far more, because Part B coinsurance never stops accumulating. The route of administration—not the drug’s list price—often determines your bill. It’s always worth asking your oncologist whether an oral or infused option is clinically appropriate, and what each would cost you specifically.

CAR-T Cell Therapy: A Major Part B Exposure

Chimeric antigen receptor (CAR) T-cell therapy—products like Yescarta, Kymriah, Breyanzi, Tecartus, Abecma, and Carvykti—has become a standard option for relapsed large B-cell lymphoma, certain leukemias, and multiple myeloma. Medicare covers CAR-T for its approved indications.

The catch is cost. The cell product alone carries a list price around $400,000–$500,000, and the total episode—including hospitalization for the infusion and management of side effects like cytokine release syndrome—can exceed $1 million.

How you’re charged depends on the setting:

• Inpatient CAR-T is paid under Part A, so your direct exposure is the Part A hospital deductible ($1,736 per benefit period in 2026) plus any daily coinsurance for a long stay—large, but bounded.
• Outpatient CAR-T is paid under Part B at 20 percent coinsurance with no cap, which against a six- or seven-figure charge would be financially ruinous without supplemental coverage.

This single fact—that a Part B percentage applied to a million-dollar therapy has no ceiling—is the strongest possible argument for the supplemental protection described below.

Hospitalization, Transplant, and Supportive Care

• Inpatient stays for induction chemotherapy (common in acute leukemia), complications, or stem cell/bone marrow transplant fall under Part A, subject to the benefit-period deductible and daily coinsurance.
• Transplant itself is covered when medically necessary, including the inpatient stay and related Part B physician services.
• Supportive drugs—anti-nausea medications, growth factors (G-CSF like filgrastim/pegfilgrastim), and transfusions—are typically billed under Part B when given in the clinic, or Part D when self-administered at home.
• Hospice under Part A covers comfort-focused care for end-stage disease, including drugs for symptom relief, at little to no cost.

For a broader view of how all cancer care fits together across Parts A, B, and D, see our Medicare cancer treatment coverage guide.

Why Supplemental Coverage Is Decisive

Because blood-cancer treatment combines uncapped Part B coinsurance (infusions, antibodies, possibly CAR-T) with potentially years of therapy, the protection you choose at enrollment can mean a difference of tens of thousands of dollars.

• Medigap Plan G pays your 20 percent Part B coinsurance with no annual limit, so even outpatient CAR-T or a long course of rituximab leaves you owing essentially only the small Part B deductible. See our comparison of Medigap plans.
• Medicare Advantage caps your in-network out-of-pocket each year (commonly $4,000–$9,000), which protects you far better than Original Medicare alone—but it adds prior authorization and network restrictions that can complicate access to a specialized cancer center or a particular CAR-T facility. Weigh the trade-offs in our Medicare Advantage vs. Original Medicare comparison and the cost-focused breakdown.

The decision is hardest the day after a diagnosis, when guaranteed-issue Medigap rights may have lapsed and underwriting can block a switch. That’s why this choice is best made when you first enroll.

Help With Drug Costs

• Extra Help (Low-Income Subsidy) dramatically lowers Part D costs—often to a few dollars per prescription—for those who qualify financially, which transforms the economics of oral targeted therapy.
• Medicare Savings Programs can pay your Part B premium and, at the QMB level, your Part B coinsurance—directly relieving the uncapped infusion exposure. See our guide to Medicare Savings Programs.
• Manufacturer and foundation assistance (Leukemia & Lymphoma Society, PAN Foundation, and drug-maker programs) can help with the $2,100 Part D cap, though rules on using them with Medicare vary.

The Bottom Line

Medicare covers the modern arsenal for leukemia and lymphoma—diagnostic testing, oral targeted pills, infused chemo and antibodies, CAR-T cell therapy, transplant, and hospice. But coverage is not the same as affordability. The $2,100 Part D cap has made expensive oral pills genuinely manageable, while uncapped Part B coinsurance on infusions and especially CAR-T remains the largest financial risk. Choosing the right supplemental coverage—ideally Medigap Plan G—and tapping Extra Help or Medicare Savings Programs where eligible is what turns world-class treatment into something you can actually afford. As with most serious diagnoses, planning your coverage before you need it is the single most valuable financial move, a theme that runs through all of our healthcare cost planning for retirement.

Frequently Asked Questions

Does Medicare cover CLL (chronic lymphocytic leukemia) specifically?

Yes. Medicare covers all standard CLL treatments: watchful waiting monitoring visits and labs under Part B, oral BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and venetoclax under Part D at the $2,100 annual cap, and infused regimens like obinutuzumab (Gazyva) under Part B at 20% coinsurance. CLL is the most common leukemia in adults over 65, and the Medicare-eligible age group is the population most affected. Because many CLL patients are managed for years before needing treatment, the recurring Part B diagnostic costs — annual blood counts, periodic bone marrow staging, CT or PET scans — add up over time even before drug therapy begins.

How much does CAR-T cell therapy cost with Medicare?

The cost depends entirely on where the infusion happens. If CAR-T is delivered as an inpatient procedure (which is standard at most centers), you pay the Part A hospital deductible — $1,736 per benefit period in 2026 — plus any applicable daily coinsurance for an extended stay. That is large but bounded. If delivered in an outpatient hospital setting, CAR-T falls under Part B at 20% coinsurance with no annual cap. Against a drug cost of $400,000–$500,000 plus a total episode cost that can exceed $1 million, 20% coinsurance in an outpatient setting would be financially ruinous without Medigap Plan G, which covers the full Part B coinsurance. Always confirm with your cancer center whether CAR-T is being arranged as an inpatient admission — the billing setting makes an enormous dollar difference.

Does Medicare cover Rituxan (rituximab) infusions?

Yes. Rituximab (Rituxan) and its biosimilars are infused IV drugs covered under Part B, meaning Medicare pays 80% and you owe 20% coinsurance with no annual cap. A single rituximab infusion cycle can cost several thousand dollars; a full course of six R-CHOP cycles for lymphoma can generate $5,000–$15,000 in Part B coinsurance for a beneficiary without supplemental coverage. Medigap Plan G eliminates this coinsurance entirely — you pay $0 beyond the annual Part B deductible for every rituximab infusion in the treatment year.

Can I get Medicare for leukemia if I’m under 65?

Yes. Medicare extends to people under 65 in two situations relevant to blood cancer patients: (1) you have received Social Security Disability Insurance (SSDI) benefits for 24 months — the two-year waiting period — after which Medicare coverage begins automatically; and (2) you have been diagnosed with End-Stage Renal Disease (ESRD). Leukemia itself is not a qualifying condition for immediate Medicare enrollment, but the SSDI pathway is available for any patient who cannot work because of leukemia, lymphoma, or related blood disorders. Given the severity of most blood cancers, many patients qualify for Social Security disability and should apply promptly — Medicare coverage begins 24 months after the SSDI entitlement date, not the application date, so early application is critical.

Does Medicare Advantage cover leukemia and lymphoma differently than Original Medicare?

Medicare Advantage must cover the same services as Original Medicare, but the cost structure and access differ. MA plans cap your annual out-of-pocket medical costs (commonly $4,000–$9,000 in-network in 2026), which provides more predictable protection than Original Medicare’s uncapped Part B coinsurance. However, blood cancer care involves several MA trade-offs: prior authorization requirements on chemotherapy regimens and targeted biologics can delay treatment start; network restrictions may limit access to specialized hematology-oncology centers or transplant programs; and MA plans often require step therapy before approving newer agents. The Medigap enrollment window (guaranteed-issue for six months starting when you turn 65 and enroll in Part B) is particularly important for blood cancer — if you enrolled in MA at 65 and are later diagnosed, switching to Medigap will generally require medical underwriting, and a blood cancer diagnosis can make Medigap coverage unavailable. Choosing a comprehensive Medigap plan at 65 — before any diagnosis — is the most robust long-term protection strategy.

Sources

• Medicare.gov — Chemotherapy coverage
• Medicare.gov — Drug coverage (Part D)
• Medicare.gov — Medicare costs

All sources are official government or nonprofit consumer resources, verified July 2026. Medicare and Social Security rules and dollar amounts change annually — confirm current figures at the links above before making decisions.